Development and Current Status of Antibody-drug conjugate (ADC)

DOI Web Site Web Site 34 References

Bibliographic Information

Other Title
  • 抗体－薬物複合体開発の発展と現状
  • コウタイ-ヤクブツ フクゴウタイ カイハツ ノ ハッテン ト ゲンジョウ

Search this article

Abstract

Antibody-drug conjugates (ADCs) are expected as next therapeutic antibodies. At present, four ADCs have been approved. ADCs consist from three components, antibody, cytotoxic agents, and linker. In this paper, recent advances of ADC developments are described. From view of antibody development, internarization ability and cancer stromal targeting therapy concept are described. For cytotoxic agents, features of representative agents including radio isotopes are described. Linker technology development for homogeneous ADC preparation is also focused. Representative bioorthogonal reaction for ADC preparation is also included.

Journal

  • Drug Delivery System

    Drug Delivery System 34 (1), 10-21, 2019-01-25

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(34)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top